Trial Profile
Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms PEARL
- 23 Sep 2023 Primary endpoint (Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment After Receiving the Investigational Combination of Preoperative Pembrolizumab and Radiation) has been met according to results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
- 23 Sep 2023 Results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference
- 25 May 2023 Planned End Date changed from 21 Apr 2023 to 21 Apr 2025.